Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection

被引:134
|
作者
Theil, FP [1 ]
Guentert, TW [1 ]
Haddad, S [1 ]
Poulin, P [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Nonclin Drug Safety, Pharma Res, CH-4070 Basel, Switzerland
关键词
drug discovery; drug development; partition coefficients; PBPK modeling; pharmacokinetics; toxicokinetics; QSAR;
D O I
10.1016/S0378-4274(02)00374-0
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The present paper proposes a modeling and simulation strategy for the prediction of pharmacokinetics (PK) of drug candidates by using currently available in silico and in vitro based prediction tools for absorption, distribution, metabolism and excretion (ADME). These methods can be used to estimate specific ADME parameters (such as rate and extent of absorption into portal vein, volume of distribution, metabolic clearance in the liver). They can also be part of a physiologically based pharmacokinetic (PBPK) model to simulate concentration-time profiles in tissues and plasma resulting from the overall PK after intravenous or oral administration. Since the ADME prediction tools are built only on commonly generated in silico and in vitro data, they can be applied already in early drug discovery, prior to any in vivo study. With the suggested methodology, the following advantages of the mechanistic PBPK modeling framework can now be utilized to explore potential clinical candidates already in drug discovery: (i) prediction of plasma (blood) and tissue PK of drug candidates prior to in vivo experiments, (ii) supporting a better mechanistic understanding of PK properties, as well as helping the development of more rationale PK-PD relationships from tissue kinetic data predicted, and hence facilitating a more rational decision during clinical candidate selection, and (iii) the extrapolation across species, routes of administration and dose levels. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 49
页数:21
相关论文
共 50 条
  • [41] Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach
    Yeo, Karen Rowland
    Jamei, Masoud
    Rostami-Hodjegan, Amin
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (02) : 143 - 157
  • [42] Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates
    Yoshikado, Takashi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2023, 143 (01): : 11 - 19
  • [43] Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases
    Muhammad F. Rasool
    Shazia Ali
    Sundus Khalid
    Ramsha Khalid
    Abdul Majeed
    Imran Imran
    Hamid Saeed
    Muhammad Usman
    Mohsin Ali
    Amer S. Alali
    Abdullah F. AlAsmari
    Nemat Ali
    Ali Mohammed Asiri
    Fawaz Alasmari
    Faleh Alqahtani
    Scientific Reports, 11
  • [44] Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases
    Rasool, Muhammad F.
    Ali, Shazia
    Khalid, Sundus
    Khalid, Ramsha
    Majeed, Abdul
    Imran, Imran
    Saeed, Hamid
    Usman, Muhammad
    Ali, Mohsin
    Alali, Amer S.
    AlAsmari, Abdullah F.
    Ali, Nemat
    Asiri, Ali Mohammed
    Alasmari, Fawaz
    Alqahtani, Faleh
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions
    Baneyx, Guillaume
    Fukushima, Yumi
    Parrott, Neil
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (05) : 681 - 693
  • [46] Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
    Jee Sun Min
    Soo Kyung Bae
    Archives of Pharmacal Research, 2017, 40 : 1356 - 1379
  • [47] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions
    Ruben de Kanter
    Patricia N. Sidharta
    Stéphane Delahaye
    Carmela Gnerre
    Jerome Segrestaa
    Stephan Buchmann
    Christopher Kohl
    Alexander Treiber
    Clinical Pharmacokinetics, 2016, 55 : 369 - 380
  • [48] Physiologically based pharmacokinetic model for drug-drug interaction in XELIRI regimen
    Sakai, Shuhei
    Kobuchi, Shinji
    Ito, Yukako
    Sakaeda, Toshiyuki
    CANCER SCIENCE, 2022, 113 : 1071 - 1071
  • [49] Utility of homology models in the drug discovery process
    Hillisch, A
    Pineda, LF
    Hilgenfeld, R
    DRUG DISCOVERY TODAY, 2004, 9 (15) : 659 - 669
  • [50] APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS FOR ASSESSING DRUG DISPOSITION IN-SPACE
    SRINIVASAN, RS
    BOURNE, DWA
    PUTCHA, L
    JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (06): : 692 - 698